[go: up one dir, main page]

WO2003056329A3 - Utilisation d'un complexe de transduction de signal dans des processus de mise au point de medicaments - Google Patents

Utilisation d'un complexe de transduction de signal dans des processus de mise au point de medicaments Download PDF

Info

Publication number
WO2003056329A3
WO2003056329A3 PCT/DK2002/000901 DK0200901W WO03056329A3 WO 2003056329 A3 WO2003056329 A3 WO 2003056329A3 DK 0200901 W DK0200901 W DK 0200901W WO 03056329 A3 WO03056329 A3 WO 03056329A3
Authority
WO
WIPO (PCT)
Prior art keywords
signal transduction
drug discovery
target molecule
biological target
transduction complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2002/000901
Other languages
English (en)
Other versions
WO2003056329A2 (fr
Inventor
Thue W Schwartz
Birgitte Holst Lange
Arne Heydorn
Rasmus Joergensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
7TM Pharma AS
Original Assignee
7TM Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 7TM Pharma AS filed Critical 7TM Pharma AS
Priority to AU2002357449A priority Critical patent/AU2002357449A1/en
Publication of WO2003056329A2 publication Critical patent/WO2003056329A2/fr
Publication of WO2003056329A3 publication Critical patent/WO2003056329A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un processus de mise au point de médicaments, qui permet d'identifier un ligand pouvant se lier à une molécule cible biologique. Le processus consiste à: a) produire un complexe de transduction de signal comprenant une molécule cible biologique, une ou plusieurs molécule(s) effectrice(s) aval et, éventuellement, une protéine adaptatrice; b) placer le ligand au contact du complexe de transduction de signal; et c) mesurer un éventuel effet résultant du processus de transduction de signal, qui se rapporte à la molécule cible biologique et à une ou plusieurs molécule(s) effectrice(s) aval. L'invention concerne un processus de mise au point de médicaments dans lequel le complexe de transduction de signal comprend un premier élément contenant une molécule cible biologique; un deuxième élément contenant une ou plusieurs protéine(s) adaptatrice(s); et un troisième élément contenant une ou plusieurs molécule(s) effectrice(s) aval. Chaque élément reconnaît ou se lie à au moins un des autres éléments pour accomplir un processus de transduction de signal. Au moins un des éléments a été modifié de manière à contenir un ou plusieurs domaine(s) et/ou un ou plusieurs motif(s) de reconnaissance.
PCT/DK2002/000901 2001-12-21 2002-12-20 Utilisation d'un complexe de transduction de signal dans des processus de mise au point de medicaments Ceased WO2003056329A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002357449A AU2002357449A1 (en) 2001-12-21 2002-12-20 Use of a signal transduction complex in drug discovery processes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101944 2001-12-21
DKPA200101944 2001-12-21

Publications (2)

Publication Number Publication Date
WO2003056329A2 WO2003056329A2 (fr) 2003-07-10
WO2003056329A3 true WO2003056329A3 (fr) 2003-11-27

Family

ID=8160930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2002/000901 Ceased WO2003056329A2 (fr) 2001-12-21 2002-12-20 Utilisation d'un complexe de transduction de signal dans des processus de mise au point de medicaments

Country Status (2)

Country Link
AU (1) AU2002357449A1 (fr)
WO (1) WO2003056329A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308204B2 (en) 2009-11-02 2016-04-12 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068863A2 (fr) 2008-12-12 2010-06-17 Cystic Fibrosis Foundation Therapeutics, Inc. Composés de pyrimidine et leurs procédés de fabrication et d'utilisation
WO2010151747A1 (fr) * 2009-06-26 2010-12-29 Cystic Fibrosis Foundation Therapeutics, Inc. Composés de pyramine ainsi que leurs procédés de fabrication et d'utilisation
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011204A2 (fr) * 1998-08-18 2000-03-02 The Johns Hopkins University School Of Medicine Proteines a interaction de la famille homer
WO2000040969A1 (fr) * 1998-12-30 2000-07-13 Sippel Albrecht E Methode de detection cellulaire a haut rendement d'interactions entre des recepteurs nucleaires et des ligands

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011204A2 (fr) * 1998-08-18 2000-03-02 The Johns Hopkins University School Of Medicine Proteines a interaction de la famille homer
WO2000040969A1 (fr) * 1998-12-30 2000-07-13 Sippel Albrecht E Methode de detection cellulaire a haut rendement d'interactions entre des recepteurs nucleaires et des ligands

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARUCH Z. HARRIS ET AL: "Mechanism and role of PDZ domains in signaling complex assembly", JOURNAL OF CELL SCIENCE, vol. 114, 2001, pages 3219 - 3231, XP002254204 *
MARK D. UNGRIN ET AL: "An Automated Aequorin Luminescence-Based Functional Calcium Assay for G-Protein-Coupled Receptors", ANALYTICAL BIOCHEMISTRY, vol. 272, 1999, pages 34 - 42, XP002254202 *
PAUL J. KAMMERMEIER ET AL: "Homer Proteins Regulate Coupling of Group I Metabotropic Glutamate Receptros to N-Type Calcium and M-Type Potassium Channels", THE JOURNAL OF NEUROSCIENCE, vol. 20, no. 19, 1 October 2000 (2000-10-01), pages 7238 - 7245, XP002254203 *
PETER COWARD ET AL: "Chimeric G Proteins Allow a High-Throughput Signaling Assay of Gi-Coupled Receptors", ANALYTICAL BIOCHEMISTRY, vol. 270, 1999, pages 242 - 248, XP002254201 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308204B2 (en) 2009-11-02 2016-04-12 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
US9439902B2 (en) 2009-11-02 2016-09-13 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
US9439901B2 (en) 2009-11-02 2016-09-13 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Also Published As

Publication number Publication date
WO2003056329A2 (fr) 2003-07-10
AU2002357449A8 (en) 2003-07-15
AU2002357449A1 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
WO2004009622A3 (fr) Complexes de proteiniques de reseaux cellulaires fondant le developpement du cancer et d'autres maladies
CA2337197A1 (fr) Microdispositifs servant a cribler des biomolecules
WO2003073817A3 (fr) Detection rapide et sensible de cellules et de virus
WO2004069211A3 (fr) Proteines d'affinite destinees a l'application controlee de substances cosmetiques
WO2002042427A3 (fr) Marqueurs de masse pour analyse quantitative
DE60329839D1 (de) Behandlung und verhütung von gewebeschäden, die mit erhöhter produktion von c-reactivem protein verbunden sind
FI953990A0 (fi) Menetelmä nukleiinihappomonistusreaktiotuotteen tekemiseksi kykenemät-tömäksi olemaan lisämonistuksen kohteena, diagnostinen määritysmenetelmä, jossa tätä menetelmää käytetään, ja menetelmän tai määrityksen toteutukseen sopiva testipakkaus ja säiliö
WO2002097125A3 (fr) Outils pour le diagnostic, la definition moleculaire et le developpement du traitement de maladies inflammatoires articulaires
WO2003002724A3 (fr) Proteines, zones de proteines pouvant etre ciblees et analyse de cibles servant a la composition chimique de medicaments
ATE283481T1 (de) Verfahren zum auffinden von reagenzien und festphasenkomponenten in spezifischen bindungsassays, frei von fortgeschrittenen glykosylierungsendprodukten
WO2001016184A3 (fr) Dosage de diagnostic pour la thrombocytopenie induite par l'heparine de type 2
WO2003056329A3 (fr) Utilisation d'un complexe de transduction de signal dans des processus de mise au point de medicaments
BR0309279A (pt) Macromoléculas em multicamadas e métodos para uso das mesmas
WO1999065947A3 (fr) Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
WO2002054326A3 (fr) Procede d'organisation et de description d'elements biologiques
WO2003020005A3 (fr) Proteines de mammiferes lp et reactifs associes
WO2001069247A3 (fr) Procedes de fabrication et d'utilisation de jeux ordonnes de micro-echantillons de matieres biologiques
WO2007067983A3 (fr) Anticorps specifique de la sulfotyrosine et utilisation a cet effet
WO2002079495A3 (fr) Applications genomiques destinees a des oligonucleotides modifies
EP0824149A3 (fr) Glutamine: fructose-6-phosphate amidotransférase (GFAT), sa production et son utilisation
WO2005007893A3 (fr) Detection universelle de liaison
WO2003040299A3 (fr) Procede de selection de ligands d'hla-dp4
ATE376595T1 (de) Nachweisverfahren mit biochip
WO2003083438A3 (fr) Procedes et systemes de modelisation moleculaire
WO2003014375A3 (fr) Molecules de sonde d'acide nucleique et methodes d'utilisation de ces dernieres

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP